{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RO4929097", "query": { "intervention": "RO4929097" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 27, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RO4929097&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-10T20:12:08.480Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01192763", "title": "RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of the Pancreas", "Stage IA Pancreatic Cancer", "Stage IB Pancreatic Cancer", "Stage IIA Pancreatic Cancer", "Stage IIB Pancreatic Cancer" ], "interventions": [ { "name": "gamma-secretase/Notch signalling pathway inhibitor RO4929097", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2010-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-09-10T20:12:08.480Z", "location_count": 6, "location_summary": "Beverly Hills, California • Duarte, California • Chicago, Illinois + 3 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Springfield", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01192763" }, { "nct_id": "NCT01193868", "title": "RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Non-small Cell Lung Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer" ], "interventions": [ { "name": "gamma-secretase/Notch signalling pathway inhibitor RO4929097", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2010-09", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2015-11-18", "last_synced_at": "2026-09-10T20:12:08.480Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01193868" }, { "nct_id": "NCT01217411", "title": "RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Solid Neoplasm", "Extensive Stage Lung Small Cell Carcinoma", "HER2/Neu Negative", "HER2/Neu Positive", "Male Breast Carcinoma", "Metastatic Malignant Neoplasm in the Brain", "Recurrent Breast Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Recurrent Lung Small Cell Carcinoma", "Recurrent Melanoma", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "Cognitive Assessment", "type": "PROCEDURE" }, { "name": "Gamma-Secretase Inhibitor RO4929097", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Whole-Brain Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2010-10-01", "completion_date": "2011-11-30", "has_results": true, "last_update_posted_date": "2024-11-19", "last_synced_at": "2026-09-10T20:12:08.480Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01217411" }, { "nct_id": "NCT01208441", "title": "RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Estrogen Receptor-positive Breast Cancer", "HER2-negative Breast Cancer", "Progesterone Receptor-positive Breast Cancer", "Stage II Breast Cancer", "Stage IIIA Breast Cancer" ], "interventions": [ { "name": "letrozole", "type": "DRUG" }, { "name": "gamma-secretase/Notch signalling pathway inhibitor RO4929097", "type": "DRUG" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "breast biopsy", "type": "PROCEDURE" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 28, "start_date": "2010-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-09-10T20:12:08.480Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Pittsburgh, Pennsylvania", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01208441" }, { "nct_id": "NCT01198535", "title": "Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colon Mucinous Adenocarcinoma", "Colon Signet Ring Cell Adenocarcinoma", "Rectal Mucinous Adenocarcinoma", "Rectal Signet Ring Cell Adenocarcinoma", "Recurrent Colon Carcinoma", "Recurrent Rectal Carcinoma", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer" ], "interventions": [ { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Gamma-Secretase Inhibitor RO4929097", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2010-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-05-18", "last_synced_at": "2026-09-10T20:12:08.480Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01198535" }, { "nct_id": "NCT01232829", "title": "Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Pancreas", "Recurrent Pancreatic Cancer", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "gamma-secretase/Notch signalling pathway inhibitor RO4929097", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2010-10", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2014-11-26", "last_synced_at": "2026-09-10T20:12:08.480Z", "location_count": 3, "location_summary": "Aurora, Colorado • Denver, Colorado • Baltimore, Maryland", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01232829" }, { "nct_id": "NCT01071564", "title": "RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Estrogen Receptor Negative", "HER2/Neu Negative", "Progesterone Receptor Negative", "Recurrent Breast Carcinoma", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Gamma-Secretase Inhibitor RO4929097", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacogenomic Study", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2009-11", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2015-04-15", "last_synced_at": "2026-09-10T20:12:08.480Z", "location_count": 3, "location_summary": "Baltimore, Maryland • Ann Arbor, Michigan • Detroit, Michigan", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01071564" }, { "nct_id": "NCT01216787", "title": "RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IIIB Melanoma", "Stage IIIC Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "gamma-secretase/Notch signalling pathway inhibitor RO4929097", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2010-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-31", "last_synced_at": "2026-09-10T20:12:08.480Z", "location_count": 2, "location_summary": "New York, New York • The Bronx, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01216787" }, { "nct_id": "NCT00532090", "title": "A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "RG4733", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2007-11", "completion_date": "2010-08", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-10T20:12:08.480Z", "location_count": 7, "location_summary": "Aurora, Colorado • Boston, Massachusetts • New Brunswick, New Jersey + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00532090" }, { "nct_id": "NCT01238133", "title": "Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Estrogen Receptor Negative", "HER2/Neu Negative", "Progesterone Receptor Negative", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gamma-Secretase Inhibitor RO4929097", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2010-12", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2015-09-04", "last_synced_at": "2026-09-10T20:12:08.480Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01238133" } ] }